封面
市場調查報告書
商品編碼
1482462

靜脈注射Ibuprofen市場:依適應症、強度、年齡層、通路、地區

Intravenous Ibuprofen Market, By Indication, By Strength, By Age Group, By Distribution Channel, By Geography

出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

到2024年,全球靜脈注射(IV)Ibuprofen市場規模估計將達到 69.1 億美元,到2031年將達到 111.3 億美元,2024年至2031年年複合成長率為 7%。

報告範圍 報告詳情
基準年 2023年 2024年市場規模 69.1億美元
實際資料 2019-2023 預測期 2024年至2031年
預測2024-2031年年複合成長率: 7.00% 2031年的預測值 111.3億美元
圖:2024年依地區分類的靜脈注射(IV)Ibuprofen市場佔有率(%)
靜脈注射布洛芬市場-IMG1

靜脈注射(IV)Ibuprofen幾十年來一直用於緩解疼痛和退燒。作為非類固醇消炎劑(NSAID)Ibuprofen的靜脈注射製劑,吸收和起效比口服給藥更快。靜脈注射(IV)Ibuprofen的作用是抑制Gland的產生,前列腺素是體內促進疼痛和發燒的荷爾蒙物質。靜脈注射時,可在15分鐘內緩解中度至重度疼痛,單劑量永續長達8小時。近年來,由於需要靜脈注射疼痛管理的疾病數量不斷增加,以及與其他鎮痛藥物相比的優勢,全球靜脈注射(IV)Ibuprofen市場近年來穩步成長。

市場動態:

患有整形外科疾病和術後疼痛的老年人數量不斷增加,發燒和疼痛疾病的盛行率不斷增加,以及靜脈注射(IV)Ibuprofen相對於口服非類固醇抗發炎藥(NSAID)的優越療效,這些都推動了靜脈注射(IV)Ibuprofen的成長。然而,長期使用和偏好非鴉片類替代品的消化道出血和腎毒性的潛在風險預計將抑制市場成長。隨著評估新適應症和劑型功效的臨床試驗進行,預計將帶來利潤豐厚的商機。

本研究的主要特點

  • 本報告詳細分析了全球靜脈注射Ibuprofen市場,並介紹了以2023年為基準年的預測期(2024-2031)的市場規模和年複合成長率(CAGR%) 。
  • 說明了各個細分市場的潛在商機,並為該市場提供了一系列有吸引力的投資提案。
  • 提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
  • 本報告根據公司亮點、產品系列、主要亮點、業績和策略等參數,介紹了全球靜脈注射Ibuprofen市場的主要參與者。
  • 本報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
  • 全球靜脈注射(IV)Ibuprofen市場迎合了該行業的各種相關人員,如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 透過用於分析全球靜脈注射Ibuprofen市場的各種策略矩陣,將促進相關人員的決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map(COM)

第3章 市場動態、法規與趨勢分析

  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
  • 影響分析
  • 市場趨勢
  • 最近的趨勢
  • 監管場景
  • 製造商收益
  • 價格分析
  • 收購和合作場景
  • 產品發布/核准
  • 資金籌措和投資
  • PEST分析
  • 波特的分析

第4章 全球靜脈注射Ibuprofen市場,COVID-19 大流行的影響

  • 整體影響
  • 政府舉措
  • COVID-19 對市場的影響

第5章 全球靜脈注射Ibuprofen市場,依適應症分類,2019-2031

  • 疼痛管理
  • 其他

第6章 全球靜脈注射Ibuprofen市場,依強度分類,2019-2031

  • 100mg
  • 200mg
  • 400mg
  • 800mg

第7章 全球靜脈注射Ibuprofen市場,依年齡層別,2019-2031

  • 小兒科
  • 成人

第8章 全球靜脈注射Ibuprofen市場,依通路分類,2019-2031

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章 2019-2031年全球靜脈注射Ibuprofen市場,依地區

第10章 競爭格局

  • 公司簡介
    • Cumberland Pharmaceuticals Inc.
    • Hyloris Pharmaceuticals SA
    • Grifols, SA
    • Recordati Rare Diseases Inc.
    • XGEN PHARMACEUTICALS DJB, Inc.
    • AFT Pharmaceuticals
    • Laboratorios Valmorca
    • SGPharma Pvt. Ltd.
    • Wellona Pharma
    • Delex Pharma
    • Hikma Pharmaceuticals PLC

第11章 分析師建議

  • 分析師觀點
  • Coherent Opportunity Map

第12章 參考文獻與調查方法

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI6901

Global intravenous (IV) ibuprofen market is estimated to be valued at USD 6.91 Bn in 2024 and is expected to reach USD 11.13 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 6.91 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 7.00% 2031 Value Projection: US$ 11.13 Bn
Figure. Intravenous (IV) Ibuprofen Market Share (%), By Region 2024
Intravenous  Ibuprofen Market - IMG1

Intravenous (IV) ibuprofen is used for pain relief and fever reduction for several decades. As an intravenous formulation of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen, it offers faster absorption and onset of action as compared to oral administration. Intravenous (IV) ibuprofen works by blocking the production of prostaglandins - hormone-like substances in the body that promote pain and fever. With intravenous delivery, it can provide relief for moderate to severe pain within 15 minutes and may be effective for up to 8 hours with a single dose. Global intravenous (IV) ibuprofen market has witnessed steady growth in recent years due to increasing prevalence of diseases requiring IV pain management and benefits over other analgesic options.

Market Dynamics:

Global intravenous (IV) ibuprofen market growth is driven by rising geriatric population suffering from orthopedic diseases and postoperative pain, growing prevalence of fever and pain conditions, and superior efficacy of IV ibuprofen over oral NSAIDs. However, potential risks of gastrointestinal bleeding and kidney toxicity with long-term use along with preference for non-opioid alternatives are expected to restrain the market growth. Ongoing clinical trials evaluating efficacy for new indications and formulations present lucrative opportunities.

Key Features of the Study:

  • This report provides in-depth analysis of the global intravenous (IV) ibuprofen market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global intravenous (IV) ibuprofen market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Grifols, S.A., Recordati Rare Diseases Inc., XGEN PHARMACEUTICALS DJB, Inc., AFT Pharmaceuticals, Laboratorios Valmorca, SGPharma Pvt. Ltd., Wellona Pharma, Delex Pharma, and Hikma Pharmaceuticals PLC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global intravenous (IV) ibuprofen market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global intravenous (IV) ibuprofen market.

Detailed Segmentation-

  • By Indication:
    • Pain Management
    • Fever
    • Others
  • By Strength:
    • 100 mg
    • 200 mg
    • 400 mg
    • 800 mg
  • By Age Group:
    • Pediatrics
    • Adults
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Cumberland Pharmaceuticals Inc.
    • Hyloris Pharmaceuticals SA
    • Grifols, S.A.
    • Recordati Rare Diseases Inc.
    • XGEN PHARMACEUTICALS DJB, Inc.
    • AFT Pharmaceuticals
    • Laboratorios Valmorca
    • SGPharma Pvt. Ltd.
    • Wellona Pharma
    • Delex Pharma
    • Hikma Pharmaceuticals PLC

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Indication
    • Market Snapshot, By Strength
    • Market Snapshot, By Age Group
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Regulatory Scenario
  • Manufacturer Revenue
  • Pricing Analysis
  • Acquisitions and Partnerships Scenario
  • Product Launches/Approvals
  • Fundings and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Intravenous (IV) Ibuprofen Market- Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Intravenous (IV) Ibuprofen Market, By Indication, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Pain Management
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Fever
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Intravenous (IV) Ibuprofen Market, By Strength, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • 100 mg
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • 200 mg
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • 400 mg
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • 800 mg
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Intravenous (IV) Ibuprofen Market, By Age Group, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Pediatrics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Adults
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Intravenous (IV) Ibuprofen Market, By Distribution Channel, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Intravenous (IV) Ibuprofen Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2031
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
      • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
      • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
      • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
      • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

10. Competitive Landscape

  • Company Profiles
    • Cumberland Pharmaceuticals Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Hyloris Pharmaceuticals SA
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Grifols, S.A.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Recordati Rare Diseases Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • XGEN PHARMACEUTICALS DJB, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • AFT Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Laboratorios Valmorca
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • SGPharma Pvt. Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Wellona Pharma
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Delex Pharma
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Hikma Pharmaceuticals PLC
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact